{
    "2018-08-27": [
        [
            {
                "time": "2018-01-02",
                "original_text": "AbbVie's Imbruvica Approved for Type of Non-Hodgkin Lymphoma",
                "features": {
                    "keywords": [
                        "Imbruvica",
                        "Non-Hodgkin Lymphoma",
                        "Approval"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "AbbVie's Rare Blood Cancer Drug Combo Snags FDA Approval",
                "features": {
                    "keywords": [
                        "Rare Blood Cancer",
                        "FDA Approval",
                        "Drug Combo"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "We Did The Math FTXH Can Go To $26",
                "features": {
                    "keywords": [
                        "FTXH",
                        "Price Target",
                        "$26"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Benzinga Pro's 5 Stocks To Watch Today",
                "features": {
                    "keywords": [
                        "Stocks To Watch",
                        "Today"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Today's Research Reports on Trending Tickers: AbbVie and Merck & Co.",
                "features": {
                    "keywords": [
                        "Research Reports",
                        "Trending Tickers",
                        "AbbVie",
                        "Merck"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer",
                "features": {
                    "keywords": [
                        "IMBRUVICA",
                        "Rituximab",
                        "FDA Approval",
                        "Chemotherapy-Free",
                        "Waldenström's Macroglobulinemia"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "AbbVie (ABBV) Up 3.7% Since Last Earnings Report: Can It Continue?",
                "features": {
                    "keywords": [
                        "ABBV",
                        "Earnings Report",
                        "Up 3.7%"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}